side-effects when given with sympathomimetics, inotropic.

Theoretical

▶ Entacapone is predicted to increase the risk of cardiovascular

side-effects when given with sympathomimetics, vasoconstrictor

(adrenaline/epinephrine, noradrenaline/norepinephrine)

o .

Study

Enteral feeds

▶ Antacids (aluminium hydroxide) increase the risk of blocked

enteral or nasogastric tubes when given with

o

enteral feeds.

Study

▶ Enteral feeds decrease the absorption of antiepileptics

(phenytoin).rStudy

▶ Enteral feeds (vitamin-K containing) potentially decrease the

anticoagulant effect of coumarins.rAnecdotal

▶ Enteral feeds (vitamin-K containing) potentially decrease the

effects of phenindione.rTheoretical

▶ Enteral feeds decrease the exposure to quinolones

(ciprofloxacin).oStudy

▶ Sucralfate increases the risk of blocked enteral or nasogastric

tubes when given with enteral feeds. Separate administration

by 1 hour.oStudy

▶ Enteral feeds

Study

decrease the exposure to theophylline.o

Enzalutamide

GENERAL INFORMATION Caution with concurrent

chemotherapy—safety and efficacy not established.

▶ Enzalutamide is predicted to markedly decrease the exposure

to abemaciclib. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

abiraterone. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

aldosterone antagonists (eplerenone). Avoid.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

alprazolam. Adjust dose.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

Study

antiarrhythmics (disopyramide, dronedarone). Avoid.r

▶ Enzalutamide is predicted to decrease the efficacy of

antiarrhythmics (propafenone).oStudy

▶ Enzalutamide is predicted to decrease the exposure to

anticholinesterases, centrally acting (donepezil).nStudy

▶ Enzalutamide is predicted to slightly decrease the exposure to

antiepileptics (brivaracetam).oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

Study

antiepileptics (perampanel). Monitor and adjust dose.o ▶ Enzalutamide is predicted to decrease the exposure to

antifungals, azoles (isavuconazole). Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

Study

antimalarials (artemether) (with lumefantrine). Avoid.r

▶ Enzalutamide is predicted to decrease the concentration of

antimalarials (piperaquine). Avoid.oTheoretical

▶ Enzalutamide is predicted to moderately decrease the

exposure to apixaban. Use with caution or avoid.rStudy

▶ Enzalutamide moderately decreases the exposure to

apremilast. Avoid.rStudy

▶ Enzalutamide is predicted to markedly decrease the exposure

to aprepitant. Avoid.oStudy

▶ Enzalutamide is predicted to moderately decrease the

o

exposure to aripiprazole. Adjust aripiprazole dose, p. 395.

Study

▶ Enzalutamide is predicted to decrease the exposure to axitinib.

Avoid or adjust dose.oStudy

▶ Enzalutamide

r

decreases the exposure to bedaquiline. Avoid.

Study

▶ Enzalutamide is predicted to decrease the exposure to

bictegravir. Avoid.oStudy

▶ Enzalutamide slightly decreases the exposure to bortezomib.

Avoid.rStudy

▶ Enzalutamide

Study

affects the exposure to bosentan. Avoid.r

▶ Enzalutamide is predicted to very markedly decrease the

exposure to bosutinib. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

brigatinib. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

buspirone. Use with caution and adjust dose.rStudy

▶ Enzalutamide moderately decreases the exposure to

cabozantinib. Avoid.oStudy

▶ Enzalutamide is predicted to decrease the exposure to calcium

channel blockers (amlodipine, felodipine, lacidipine,

lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and

adjust dose.oStudy

▶ Enzalutamide is predicted to decrease the exposure to calcium

channel blockers (diltiazem, verapamil).rStudy

▶ Enzalutamide is predicted to decrease the exposure to

cannabis extract. Avoid.rTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

cariprazine. Avoid.rTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

ceritinib. Avoid.rStudy

▶ Enzalutamide

r

decreases the concentration of ciclosporin.

Study

▶ Enzalutamide

o

is predicted to alter the effects of cilostazol.

Theoretical

▶ Enzalutamide is predicted to decrease the exposure to

cinacalcet. Monitor and adjust dose.oStudy

1450 Encorafenib — Enzalutamide BNF 78

Interactions | Appendix 1

A1

▶ Enzalutamide decreases the exposure to clomethiazole.

Monitor and adjust dose.oStudy

▶ Clopidogrel moderately increases the exposure to

enzalutamide

Study

. Avoid or adjust enzalutamide dose, p. 947.r

▶ Enzalutamide is predicted to decrease the exposure to

clozapine.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

cobicistat. Avoid.rTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

cobimetinib. Avoid.rTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

corticosteroids (budesonide, deflazacort, dexamethasone,

fludrocortisone, hydrocortisone, methylprednisolone,

prednisolone, triamcinolone)

o

. Monitor and adjust dose.

Study

▶ Enzalutamide is predicted to decrease the exposure to

corticosteroids (fluticasone).qTheoretical

▶ Enzalutamide potentially decreases the exposure to coumarins.

Avoid or adjust dose and monitor INR.rStudy

▶ Enzalutamide is predicted to markedly decrease the exposure

to crizotinib. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

dabrafenib. Avoid.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

darifenacin.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

dasabuvir. Avoid.rTheoretical

▶ Enzalutamide is predicted to markedly decrease the exposure

to dasatinib. Avoid.rStudy

▶ Enzalutamide is predicted to slightly decrease the exposure to

delamanid. Avoid.oStudy

▶ Enzalutamide decreases the exposure to dolutegravir. Adjust

dose.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

doravirine. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to elbasvir.

Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

eliglustat. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the concentration of

elvitegravir. Avoid.rTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

encorafenib.rTheoretical

▶ Enzalutamide is predicted to decrease the effects of

ergotamine.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

erlotinib. Avoid or adjust erlotinib dose, p. 979.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

esketamine. Adjust dose.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

etravirine. Avoid.rTheoretical

▶ Enzalutamide is predicted to decrease the concentration of

everolimus. Avoid or adjust dose.rStudy

▶ Enzalutamide moderately decreases the exposure to

exemestane.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

fesoterodine. Avoid.oStudy

▶ Fibrates (gemfibrozil) moderately increase the exposure to

enzalutamide

Study

. Avoid or adjust enzalutamide dose, p. 947.r

▶ Enzalutamide is predicted to decrease the exposure to

fingolimod.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

fosaprepitant. Avoid.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

gefitinib. Avoid.rStudy

▶ Enzalutamide is predicted to greatly decrease the

concentration of glecaprevir. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

grazoprevir. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the concentration of

guanfacine. Adjust guanfacine dose, p. 352.oStudy

▶ Enzalutamide decreases the concentration of haloperidol.

Adjust dose.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

ibrutinib. Avoid or adjust ibrutinib dose, p. 983.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

idelalisib. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

imatinib. Avoid.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

irinotecan. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

ivabradine. Adjust dose.oTheoretical

▶ Enzalutamide is predicted to moderately to markedly decrease

the exposure to ivacaftor. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

ixazomib. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

lapatinib. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

linagliptin.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

lomitapide. Monitor and adjust dose.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

lurasidone. Avoid.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

macitentan. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

maraviroc. Adjust dose.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

midazolam. Monitor and adjust dose.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

midostaurin. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

mirtazapine. Adjust dose.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

montelukast.nStudy

▶ Enzalutamide is predicted to markedly decrease the exposure

to naloxegol. Avoid.oStudy

▶ Enzalutamide is predicted to slightly decrease the exposure to

nateglinide.nStudy

▶ Enzalutamide is predicted to decrease the exposure to

netupitant. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

nevirapine.rTheoretical

▶ Enzalutamide is predicted to moderately decrease the

exposure to nilotinib. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

nitisinone. Adjust dose.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

olaparib. Avoid.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

ombitasvir. Avoid.rTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

ondansetron.oStudy

▶ Enzalutamide is predicted to decrease the exposure to opioids

(alfentanil, fentanyl).oStudy

▶ Enzalutamide is predicted to decrease the exposure to opioids

(buprenorphine). Monitor and adjust dose.oTheoretical

▶ Enzalutamide decreases the exposure to opioids (methadone).

Monitor and adjust dose.rStudy

▶ Enzalutamide is predicted to decrease the exposure to opioids

(oxycodone). Monitor and adjust dose.oStudy

▶ Enzalutamide is predicted to moderately decrease the

exposure to osimertinib. Avoid.oStudy

▶ Enzalutamide is predicted to moderately decrease the

exposure to ospemifene.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

palbociclib. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

paliperidone. Monitor and adjust dose.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

panobinostat. Avoid.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

paritaprevir

Study

(with ritonavir and ombitasvir). Avoid.r

▶ Enzalutamide is predicted to decrease the exposure to

pazopanib. Avoid.rTheoretical

BNF 78 Enzalutamide — Enzalutamide 1451

Interactions | Appendix 1

A1

Enzalutamide (continued)

▶ Enzalutamide is predicted to decrease the exposure to

r

phosphodiesterase type-5 inhibitors (avanafil, tadalafil). Avoid.

Study

▶ Enzalutamide is predicted to decrease the exposure to

o

phosphodiesterase type-5 inhibitors (sildenafil, vardenafil).

Theoretical

▶ Enzalutamide is predicted to moderately to markedly decrease

the exposure to pibrentasvir. Avoid.rStudy

▶ Enzalutamide is predicted to moderately decrease the

exposure to pitolisant.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

ponatinib. Avoid.oTheoretical

▶ Enzalutamide is predicted to markedly decrease the exposure

to praziquantel. Avoid.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

quetiapine.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

ranolazine. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

reboxetine.oAnecdotal

▶ Enzalutamide is predicted to decrease the exposure to

regorafenib. Avoid.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

repaglinide

Study

. Monitor blood glucose and adjust dose.o ▶ Enzalutamide is predicted to markedly decrease the exposure

to ribociclib. Avoid.rStudy

▶ Enzalutamide markedly decreases the exposure to rilpivirine.

Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

risperidone. Adjust dose.oStudy

▶ Enzalutamide is predicted to moderately decrease the

exposure to rivaroxaban. Avoid unless patient can be

monitored for signs of thrombosis.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

roflumilast. Avoid.oStudy

▶ Enzalutamide is predicted to markedly decrease the exposure

to rolapitant. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

ruxolitinib. Monitor and adjust dose.oStudy

▶ Enzalutamide is predicted to moderately decrease the

exposure to saxagliptin.oStudy

▶ Enzalutamide is predicted to decrease the concentration of

sirolimus. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

solifenacin.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

sorafenib.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to statins

(simvastatin).rStudy

▶ Enzalutamide is predicted to decrease the exposure to

sunitinib. Avoid or adjust sunitinib dose, p. 999.oStudy

▶ Enzalutamide decreases the concentration of tacrolimus.

Monitor and adjust dose.rStudy

▶ Enzalutamide is predicted to decrease the exposure to taxanes

(cabazitaxel, paclitaxel). Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to taxanes

(docetaxel).rTheoretical

▶ Enzalutamide is predicted to decrease the concentration of

temsirolimus. Avoid.rStudy

▶ Enzalutamide decreases the exposure to tetracyclines

(doxycycline). Monitor and adjust dose.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

tezacaftor. Avoid.rTheoretical

▶ Enzalutamide is predicted to markedly decrease the exposure

to ticagrelor. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

tivozanib.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

tofacitinib. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

tolvaptan

r

. Use with caution or avoid depending on indication.

Study

▶ Enzalutamide is predicted to decrease the exposure to

toremifene. Adjust dose.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

trabectedin. Avoid.rTheoretical

▶ Enzalutamide is predicted to markedly decrease the exposure

rto ulipristal. Avoid and for 4 weeks after stopping ulipristal.

Theoretical

▶ Enzalutamide is predicted to decrease the exposure to

vandetanib. Avoid.oStudy

▶ Enzalutamide is predicted to moderately decrease the

exposure to velpatasvir. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

vemurafenib. Avoid.rTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

venetoclax. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to vinca

alkaloids (vinblastine, vincristine, vindesine).rTheoretical

▶ Enzalutamide is predicted to decrease the exposure to vinca

alkaloids (vinflunine). Avoid.rTheoretical

▶ Enzalutamide is predicted to decrease the exposure to vinca

alkaloids

Theoretical

(vinorelbine). Use with caution or avoid.r

▶ Enzalutamide is predicted to decrease the exposure to

vismodegib. Avoid.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

vortioxetine. Monitor and adjust dose.oStudy

▶ Enzalutamide is predicted to decrease the concentration of

voxilaprevir. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

zopiclone. Adjust dose.oStudy

Ephedrine → see sympathomimetics, vasoconstrictor

Epirubicin → see anthracyclines

Eplerenone → see aldosterone antagonists

Epoetin alfa → see TABLE 5 p. 1375 (thromboembolism), TABLE 16

p. 1379 (increased serum potassium)

Epoetin beta → see TABLE 5 p. 1375 (thromboembolism), TABLE 16

p. 1379 (increased serum potassium)

Epoetin zeta → see TABLE 5 p. 1375 (thromboembolism), TABLE 16

p. 1379 (increased serum potassium)

Epoprostenol → see TABLE 4 p. 1375 (antiplatelet effects)

Eprosartan → see angiotensin-II receptor antagonists

Eptifibatide → see TABLE 4 p. 1375 (antiplatelet effects)

Ergocalciferol → see vitamin D substances

Ergometrine

▶ Antiarrhythmics (dronedarone) are predicted to increase the

risk of ergotism when given with

Theoretical

ergometrine.r

▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole)

are predicted to increase the risk of ergotism when given with

ergometrine.rTheoretical

▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are

predicted to increase the risk of ergotism when given with

ergometrine. Avoid.rTheoretical

▶ Antifungals, azoles (miconazole) are predicted to increase the

exposure to ergometrine. Avoid.oTheoretical

▶ Aprepitant is predicted to increase the risk of ergotism when

given with ergometrine.rTheoretical

▶ Beta blockers, non-selective are predicted to increase the risk

of peripheral vasoconstriction when given with

r

ergometrine.

Comments

Search This Blog

Archive

Show more

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

علاقة البيبي بالفراولة بالالفا فيتو بروتين

التغيرات الخمس التي تحدث للجسم عند المشي

إحصائيات سنة 2020 | تعداد سكَان دول إفريقيا تنازليا :

ما هو الليمونير للأسنان ؟

ACUPAN 20 MG, Solution injectable

CELEPHI 200 MG, Gélule

الام الظهر

VOXCIB 200 MG, Gélule

ميبستان

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

Kana Brax Laberax

TRIPASS XR تري باس

PARANTAL 100 MG, Suppositoire بارانتال 100 مجم تحاميل

الكبد الدهني Fatty Liver

الم اسفل الظهر (الحاد) الذي يظهر بشكل مفاجئ bal-agrisi

SEDALGIC 37.5 MG / 325 MG, Comprimé pelliculé [P] سيدالجيك 37.5 مجم / 325 مجم ، قرص مغلف [P]

نمـو الدمـاغ والتطـور العقـلي لـدى الطفـل

CELEPHI 200 MG, Gélule

أخطر أنواع المخدرات فى العالم و الشرق الاوسط

Archive

Show more